Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
Venetoclax/Carfilzomib Combo Highly Effective for t(11;14) Myeloma
June 2nd 2018The addition of venetoclax to carfilzomib and dexamethasone demonstrated a 100% objective response rate with a very good partial response or better rate of 86% for patients with relapsed/refractory t(11;14) multiple myeloma.
Read More
Studies Stopped for Daratumumab/Checkpoint Inhibitor Combos in NSCLC, Myeloma
May 29th 2018Two separate early-phase clinical trials exploring daratumumab in combination with either a PD-1 inhibitor for multiple myeloma or a PD-L1 inhibitor for non–small cell lung cancer were terminated following a planned interim analysis.
Read More
FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma
May 19th 2018The FDA has issued a drug safety notification warning against the use of frontline single-agent immune checkpoint inhibition for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.
Read More
Shorter Trastuzumab Duration Matches 12-Month Standard for Early HER2+ Breast Cancer
May 17th 2018A shorter 6-month course of adjuvant trastuzumab (Herceptin) was found to be noninferior for disease-free survival compared with the standard 12-month schedule for patients with HER2-positive early breast cancer.
Read More
FDA Approves Frontline Daratumumab/VMP Combo for Multiple Myeloma
May 8th 2018The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Read More
Regorafenib HCC Benefits Consistent in Additional Analyses
April 30th 2018Second-line regorafenib (Stivarga) continued to show antitumor activity regardless of prior dose or time to progression on frontline sorafenib (Nexavar) for patients with unresectable advanced hepatocellular carcinoma.
Read More
PARP Inhibitors Arrive for BRCA+ Breast Cancer
March 11th 2018The PARP inhibitors have finally become available for patients with BRCA-mutant metastatic breast cancer, ushering in a potential new era for targeted therapies with studies currently ongoing in the adjuvant setting and exploring combinations.
Read More
Triplet Therapy May Be on the Horizon for BRAF-Mutant Melanoma
February 21st 2018The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs.
Read More
Bristol-Myers Squibb Gains NKTR-214 Access in Nektar Collaboration
February 15th 2018Bristol-Myers Squibb and Nektar Therapeutics have announced plans to jointly develop and market combinations of the CD122-biased cytokine NKTR-214 with nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) across for 20 indications in 9 tumor types.
Read More
FDA Approves Abiraterone for High-Risk Prostate Cancer
February 8th 2018The FDA has approved abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk patients with metastatic hormone-naïve prostate cancer or newly-diagnosed metastatic hormone-sensitive prostate cancer.
Read More
Enzalutamide More Than Doubles MFS for Nonmetastatic CRPC
February 6th 2018Treatment with the combination of enzalutamide and androgen deprivation therapy reduced the risk of metastases or death by 71% compared with ADT alone in patients with nonmetastatic castration-resistant prostate cancer.
Read More
FDA Grants Priority Review to Frontline Daratumumab for Multiple Myeloma
January 22nd 2018The FDA has granted a priority review designation to daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Read More
FDA Approves Arsenic Trioxide for Promyelocytic Leukemia
January 16th 2018The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.
Read More
FDA Grants Priority Review to Novel Iobenguane I-131 Agent for Rare Neuroendocrine Tumors
December 29th 2017The FDA has granted a priority review designation to a novel version of the radiopharmaceutical iobenguane I-131 for patients with malignant or recurrent pheochromocytoma or paraganglioma.
Read More
FDA Approval Sought for Ivosidenib in IDH1+ AML
December 26th 2017A new drug application has been submitted for ivosidenib for patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.
Read More